Heart failure: Statins for all?

Heart

Volumn 92, Issue 11, 2006, Pages 1537-1538

  Leite Moreira, Adelino ^a   Castro Chaves, P ^a  

^a University of Porto   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FLUINDOSTATIN; INTERLEUKIN 6; PLACEBO; SIMVASTATIN; STATIN; TUMOR NECROSIS FACTOR ALPHA;

DISEASE COURSE; DISEASE SEVERITY; EDITORIAL; FOLLOW UP; HEART FAILURE; HEART FUNCTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT;

ENDOTHELIUM, VASCULAR; HEART FAILURE, CONGESTIVE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; TREATMENT OUTCOME;

EID: 33750339154     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2006.089797     Document Type: Editorial

References (16)

1. Cohn JN, Quyyumi AA, Hollenberg NK, et al. Surrogate markers for cardiovascular disease: functional markers. Circulation 2004; 109(25 suppl 1):IV31-46.
2. Moens AL, Goovaerts I, Claeys MJ, et al. Flow-mediated vasodilation: a diagnostic instrument, or an experimental tool? Chest 2005;127:2254-63.
3. Schachinger V, Britten MB, Zeiner AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899-906.
4. Gokce N, Keaney JF Jr, Hunter LM, et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 2003;41:1769-75.
5. Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
6. Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet 2000;356:930-3.
7. Strey CH, Young JM, Lainchbury JH, et al. Short-term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure. Heart 2006;92:1603-9.
8. von Hoehling S, Anker SD. Statins for heart failure: at the crossroads between cholesterol reduction and pleiotropism? Heart 2005;91:1-2.
9. Krum H, McMurray JJ. Statins and chronic heart failure: do we need a large-scale outcome trial? J Am Coll Cardiol 2002;39:1567-73.
10. Hayashidani S, Tsutsui H, Shiomi T, et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002;105:868-73.
11. Node K, Fujita M, Kitakaze M, et al. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003;108:839-43.
12. Fukuta H, Sane DC, Brucks S, et al. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 2005;112:357-63.
13. Ray JG, Gong Y, Sykora K, et al. Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med 2005;165:62-7.
14. Sola S, Mir MQ, Lerakis S, et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 2006;47:332-7.
15. Mozaffarian D, Minami E, Letterer RA, et al. The effects of atorvastatin (10 mg) on systemic inflammation in heart failure. Am J Cardiol 2005;96:1699-704.
16. Bleske BE, Nicklas JM, Bard RL, et al. Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. J Am Coll Cardiol 2006;47:338-41.